FF 
Principal Investigator/Program Director (Last, first, middle): 
BIOGRAPHICAL SKETCH 
Give the following information for the key personnel and consultants and collaborators. Begin with the principal 
investigator/program director. Photocopy this page for each person. 
NAME POSITION TITLE 
HEIDEMAN, Richard L. Associate Member, Hematology/Oncology 
EDUCATION (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.) 
INSTITUTION AND LOCATION 
DEGREE 
YEAR 
CONFERRED 
FIELD OF STUDY 
University of Minnesota 
B.A. 
1969 
Physiologic Psy- 
chology, Chemistry 
University of Minnesota 
M.D. 
1972 
Medicine 
Medical School 
RESEARCH AND PROFESSIONAL EXPERIENCE: Concluding with present position, list, in chronological order, previous employment, experience, and 
honors. Key personnel include the principal investigator and any other individuals who participate in the scientific development or execution of the project. 
Key personnel typically will include all individuals with doctoral or other professional degrees, but in some projects will include individuals at the masters or 
baccalaureate level provided they contribute in a substantive way to the scientific development or execution of the project. Include present membership on 
any Federal Government public advisory committee. List, in chronological order, the titles, all authors, and complete references to all publications during the 
past three years and to representative earlier publications pertinent to this application. DO NOT EXCEED TWO PAGES. 
1974-1976 
1976-85 
1979-85 
1985-89 
1989 to 
present 
Postdoctoral Fellow, Pediatric Hematology/Oncology , Department of 
Pediatrics, Baylor College of Medicine, Houston, TX 
Pediatric Oncologist, Oncology/Hematology Department, The Children's 
Hospital, Denver, CO 
Assistant Professor of Pediatrics, Department of Pediatrics, University 
of Colorado Health Sciences Center, Denver, CO 
Cancer Expert and Associate Investigator, Pediatric Branch, National 
Cancer Institute, National Institutes of Health, Bethesda, MD 
Associate Member, Hematology /Oncology, St. Jude Children's Research 
Hospital, Memphis, TN 
PUBLICATIONS 
Balis FM, Lange BJ, Packer RJ, Holcenberg JS, Ettinger LJ, Sallan SE, Heideman RL, 
Zimm S, Smithson WA, Coglisno-Shutta NA, Reaman GH, Poplack DG. Pediatric Phase I 
Trial and Pharmacokinetic Study of Tiazofurin (NSC 286 193). Cancer Res 45:5169-5172, 
1985. 
Heideman RL, McGavran L, Waldstein G. Nepohroblastomatosis and lip-; The potential 
relationship to subsequent Wilms' tumor. J Pediatr Hematol Oncol 8:231-234, 1986. 
Haces A, Driscoll JS, Roth JS, Heideman RL, Kelley JA. Spiromustine Analogues. 
Relationships Between Structure, Plasma Stability and Antitumor Activity. J Pharm Sci 
75:313-316, 1986. 
Albin RE, O'Donnell RS, Hendee RW, Heideman RL, Bailey WC, Majure JA. 
Rhabdomyosarcoma of pterygoid fossa: Resection for cure utilizing an inverted facial 
flap and craniofacial reconstruction. Cancer 58:163-168, 1986. 
Wara WM, Edwards HS, Levin YA, Heideman R, Urtason R, Diaz R, Silver P, Sposto R. A 
new treatment regimen for brain stem glioma: A pilot study of the brain tumor 
research center and children's cancer study group. Int J Radiat Oncol Biol Phys 
12:143, 1986. 
Heideman RL, Balis FM, Zimm S, Lester CM, Poplack DG. The effect of Amitriptyline on 
the central nervous system penetration of methotrexate. Cancer Drug Deliv 3:219-222, 
1986. 
PHS 398 (Rev. 9/91 ) (Form Page 6) Page 
Number pages consecutively at the bottom throughout the application. Do not use suffixes such as 3a, 3b. 
Recombinant DNA Research, Volume 18 
[339] 
